Recent Updates — INBX
Inhibrx Biosciences posted an updated corporate presentation on September 28, 2026, detailing clinical data for its pipeline candidates. For INBRX-106 (ozekibart), the company reported interim results from the HexAgon study in first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The combination of INBRX-106 with pembrolizumab demonstrated a confirmed objective response rate (cORR) of 48.3% versus 26.5% for pembrolizumab alone, with median progression-free survival of 9.6 months compared to 4.9 months. In HPV-positive patients, cORR reached 80% versus 33%, and the Phase 2 portion is expanding to include 50 additional HPV+ patients to pursue an accelerated approval path by late 2028 or early 2029. For INBRX-109 (ozekibart), registrational data in chondrosarcoma showed a median progression-free survival of 5.52 months versus 2.66 months for placebo, with a hazard ratio of 0.479. The company also plans to meet with the FDA regarding colorectal cancer trial design and presented preclinical glioblastoma data. Inhibrx Biosciences operates in the biotechnology industry, focusing on discovering and developing novel protein-engineered biologics for oncology.
On September 8, 2026, Inhibrx Biosciences announced primary endpoint results from the Phase 2 portion of its HexAgon study evaluating INBRX-106 plus pembrolizumab versus pembrolizumab monotherapy in first-line HNSCC. The combination arm achieved a confirmed objective response rate (cORR) of 48.3% compared to 26.5% for the control, with median progression-free survival (PFS) of 9.6 months versus 4.9 months. Efficacy was particularly pronounced in HPV-positive patients, who demonstrated an 80.0% cORR and a 90.0% six-month PFS rate compared to 33.3% and 33.0%, respectively. Inhibrx plans to expand the trial by approximately 50 additional HPV+ patients to support a potential accelerated regulatory pathway, followed by a Phase 3 confirmatory study. The company is also advancing INBRX-106 in perioperative non-small cell lung cancer with results expected mid-2027. Inhibrx Biosciences operates as a clinical-stage biopharmaceutical company developing novel biologic therapeutic candidates.
Inhibrx Biosciences, Inc. entered into a second amendment to its loan and security agreement with Oxford Finance LLC, expanding the total credit facility to $500.0 million. The amendment includes a $325.0 million additional tranche consisting of a $100.0 million Term C Loan, which was immediately funded, and a potential $225.0 million Term D Loan. As part of the Term C funding, the company issued warrants to purchase 21,457 shares of common stock at an exercise price of $93.21 per share. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates.
On June 15, 2026, the FDA accepted the Biologics License Application (BLA) for ozekibart (INBRX-109) for treating unresectable or metastatic conventional chondrosarcoma. The FDA reported no filing review issues and set a PDUFA goal date of April 14, 2027. Inhibrx Biosciences is a biotechnology company that develops therapeutic proteins.